Imlygic Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited options for unresectable melanoma, early immunotherapy breakthroughs, rising melanoma incidence, clinical validation of viral oncology, oncology center adoption.

The growth in the forecast period can be attributed to expansion of cancer immunotherapy pipelines, increased combination oncology trials, growing investment in viral therapeutics, rising melanoma diagnosis rates, advancements in genetic modification technologies. Major trends in the forecast period include growth of oncolytic viral therapies, rising interest in immuno oncology, expansion of injectable cancer therapies, focus on localized tumor treatment, increasing combination therapy approaches.

The rising incidence of melanoma is expected to propel the growth of the Imlygic market moving forward. Melanoma is a type of skin cancer that develops in melanocytes, the cells responsible for producing pigment in the skin. The incidence of melanoma is increasing due to factors such as prolonged sun exposure, tanning bed use, and genetic predisposition. Imlygic (talimogene laherparepvec) is an oncolytic viral therapy that is injected directly into melanoma tumors to promote local tumor destruction and stimulate a systemic anti-tumor immune response. For example, in December 2023, the National Library of Medicine, a US-based biomedical library, reported that the number of melanoma cases in the EU-27 (the 27 member countries of the European Union) was 101,510 in 2022, with projections to rise to 115,540 by 2040. As a result, the growing incidence of melanoma is driving the expansion of the Imlygic market.

The global expansion of healthcare infrastructure is expected to drive the growth of the Imlygic market moving forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, resources, and systems necessary to deliver healthcare services to a population. Factors such as an aging global population, the increase in chronic diseases, and technological advancements are contributing to the global expansion of healthcare infrastructure. The progress of Imlygic relies on strong healthcare infrastructure to support its specialized storage, administration, and coordinated delivery as an oncolytic therapy. For example, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the United States rose to 6,129, reflecting a 0.591% increase from the 6,093 hospitals recorded in the previous year. Therefore, the global expansion of healthcare infrastructure is playing a key role in driving the growth of the Imlygic market.

The increase in research and development funding for cancer is also expected to drive the growth of the Imlygic market. Cancer research and development funding refers to the financial support allocated to advancing cancer treatment, prevention, and research initiatives. The rising global cancer burden, the demand for innovative therapies, and advancements in precision medicine are key drivers behind the increase in cancer R&D funding. This growing investment accelerates innovation, clinical trials, and awareness, which fosters advancements and broader adoption of therapies like Imlygic. For instance, in July 2025, the National Cancer Institute (NCI), a US-based government agency, reported that in fiscal year 2023, the NCI had $7.2 billion in available funding (including $216 million from the Cures Act), representing a 5.7% increase, or $387.5 million more than the previous year. Consequently, the increasing research and development funding for cancer is fueling the growth of the Imlygic market.

Major companies operating in the imlygic market are Amgen Inc.

North America was the largest region in the imlygic market in 2025. The regions covered in the imlygic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the imlygic market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the imlygic market by increasing costs related to viral vector production, cold chain handling, and specialized oncology distribution. These impacts are most visible in hospital and specialty oncology clinic segments, particularly in regions reliant on imported oncolytic therapies. Higher tariffs can influence pricing strategies and restrict access in emerging oncology markets. However, tariffs are also driving investment in regional manufacturing, improved supply chain resilience, and long term development of domestic viral therapy capabilities.

The imlygic market research report is one of a series of new reports that provides imlygic market statistics, including imlygic industry global market size, regional shares, competitors with a imlygic market share, detailed imlygic market segments, market trends and opportunities, and any further data you may need to thrive in the imlygic industry. This imlygic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Imlygic is a prescription medication used to treat certain types of cancer. It is an oncolytic viral therapy that utilizes a genetically modified virus to target and destroy cancer cells. Derived from the herpes simplex virus type 1 (HSV-1), Imlygic is approved for treating melanoma lesions that cannot be surgically removed.

The primary patient demographics for Imlygic include both pediatric and adult patients. Pediatric patients are individuals from birth to 18 years old who are under medical care. Imlygic (talimogene laherparepvec) may also be investigated in clinical trials for specific cancers like melanoma. It is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies, for applications such as melanoma treatment, combination therapy, and the treatment of other cancer types.

The imlygic market consists of sales of imlygic intralesional injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.